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Abstract
We have previously shown that vaccination of HLA-A2
metastatic melanoma patients with the analogue Melan-
A26-35(A27L) peptide emulsified in a mineral oil induces ex vivo
detectable specific CD8 T cells. These are further enhanced
when a TLR9 agonist is codelivered in the same vaccine
formulation. Interestingly, the same peptide can be efficiently
recognized by HLA-DQ6–restricted CD4 T cells. We used HLA-
DQ6 multimers to assess the specific CD4 T-cell response in
both healthy individuals and melanoma patients. We report
that the majority of melanoma patients carry high frequencies
of naturally circulating HLA-DQ6–restricted Melan-A–specific
CD4 T cells, a high proportion of which express FOXP3 and
proliferate poorly in response to the cognate peptide. Upon
vaccination, the relative frequency of multimer+ CD4 T cells
did not change significantly. In contrast, we found a marked
shift to FOXP3-negative CD4 T cells, accompanied by robust
CD4 T-cell proliferation upon in vitro stimulation with
cognate peptide. A concomitant reduction in TCR diversity
was also observed. This is the first report on direct ex vivo
identification of antigen-specific FOXP3+ T cells by multimer
labeling in cancer patients and on the direct assessment of the
impact of peptide vaccination on immunoregulatory T cells.
[Cancer Res 2009;69(20):8085–93]
Introduction
Specific immunotherapy is a promising approach (1–3) to the
treatment of a wide range of medical conditions including chronic
viral diseases, autoimmune inflammatory disorders, and various
types of cancer. The discovery of tumor-associated antigens
recognized by conventional ah T cells provided the foundation
for the design of defined antigen-based cancer vaccines (4).
Important to the process of rational vaccine development,
monitoring of antigen-specific T-cell responses helps guiding
vaccine optimization.
A large number of clinical trials using T-cell–defined antigens
have been reported in practically all types of cancer (5). Metastatic
melanoma is however the best studied tumor type in terms of
immune reactivity and experimental vaccine testing (6). Among the
numerous antigens expressed by cutaneous melanoma, Melan-A/
Mart-1 (hereafter Melan-A) is one of the best characterized thus far.
The Melan-A gene encodes a 118 amino acid long polypeptide
expressed by normal melanocytes and the majority of primary and
metastatic tumors (7). Interestingly, most of the Melan-A–specific
T-cell responses identified in advanced tumor-bearing patients
focus on the region spanning residues 20 to 40. In particular, the
peptide 26 to 35 defines epitopes recognized by HLA-A2– and HLA-
B35–restricted CD8 T cells (8–10). Slightly longer peptides contain-
ing the same core sequence are recognized by HLA-B45 (11) and
-B447 restricted CD8 Tcells. Moreover, the 25 to 36 dodecapeptide is
recognized byHLA-DQ6–, HLA-DQ3–, andHLA-DR3–restricted CD4
T cells (12). This pronounced bias in processing and presentation of
the Melan-A antigens is reminiscent of immunodominant protein
regions and lends itself to detailed analysis of melanoma-specific
CD8 and CD4 T-cell responses in defined clinical situations such as
tumor progression, tumor cell death provoked by chemotherapy or
radiotherapy, and in the course of immunotherapy. More impor-
tantly, such immunodominant region(s) are excellent candidates
for peptide-based vaccines because of the promise to efficiently
promote integrated protective T-cell responses (13–16).
We have shown that the natural Melan-A26-35 decapeptide binds
weakly to the HLA-A2 molecule because of the lack of a strong
anchor residue at position P2. The replacement of Ala at position
27 for Leu results in enhanced binding to HLA-A2, in 2- to 3-log
increase of its relative antigenicity and, more importantly, to an
increased immunogenicity (17). Vaccination of metastatic melano-
ma patients with the peptide analogue Melan-A26-35(A27L) emulsi-
fied in mineral oil resulted in high frequencies of Melan-A–specific
CD8 T cells that can be detected by direct ex vivo flow cytometry
analysis using HLA-A2/Melan-A peptide multimers in f60% of
vaccinated patients (18, 19). Moreover, vaccination efficiency can
be dramatically enhanced by inclusion of the TLR9 agonist ODN-
CpG type B 7909/PF-3512676 in the immunizing emulsion. In this
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case, strong specific CD8 T-cell responses as measured by multimer
labeling developed rapidly in all vaccinated patients (20).
A search for CD4 T-cell epitopes in the Melan-A polypeptide
revealed that a dodecapeptide spanning the region 25 to 36 was
optimally recognized by Melan-A–specific and tumor-reactive CD4
T cells isolated from melanoma patients (12). Moreover, HLA-DQ6/
Melan-A25-36 multimers directly identified specific CD4 T cells by
flow cytometry. Interestingly, this optimal CD4 T-cell epitope fully
encompasses the HLA-A2–restricted decapeptide Melan-A26-35. In
this report, we used HLA-DQ6/Melan-A peptide multimers to
analyze in detail Melan-A–specific CD4 T-cell responses in healthy
individuals (HD) and a cohort of HLA-A*0201 metastatic melanoma
patients who shared expression of the HLA-DQB1*0602 allele. We
found relatively high frequencies of circulating HLA-DQ6/Melan-A
multimer+ CD4 T cells in most melanoma patients studied. Fine
specificity studies of a series of clones isolated from some of these
patients showed efficient cross-recognition of the enhanced Melan-
A26-35(A27L) decapeptide. The multimer+ CD4 T cells contained high
proportions of FOXP3+ cells in the blood samples before peptide
vaccination. In contrast, the proportions of FOXP3+ cells were
markedly reduced among the multimer+ CD4 T cells, but not in the
multimer- fractions, in blood samples obtained during the course of
Melan-A peptide vaccination. Thus, although vaccination elicited
the intended HLA-A2–restricted CD8 T-cell response, it also trig-
gered an unexpected effect on specific CD4 T cells in the subset of
HLA-DQ6–vaccinated patients.
Materials and Methods
Cells and tissues. Peripheral blood and metastatic lymph nodes were
obtained from melanoma patients upon informed consent. Clinical char-
acteristics and treatments of the patients included in the study are de-
scribed in Table 1. Treatments of the patients were approved by the
institutional review board of the University Hospital of Lausanne, Swiss
Medic and the Ludwig Institute for Cancer Research Ltd. The healthy
subjects were blood donors at the Blood transfusion Center in Bern,
Switzerland. Mononuclear cells were purified by density gradient and im-
mediately frozen, as previously described (21). Genomic DNA was extracted
from frozen peripheral blood mononuclear cells (PBMC) and all individuals
were molecularly typed for HLA-DQB1*0602 by reverse PCR–sequence-
specific oligonucleotides hybridization on microbeads arrays (LabType,
OneLambda), using the luminex technology. Lymphocytes were maintained
in culture as already described (12).
Generation of pMHC I and II multimers; monoclonal antibodies and
labeling. The generation of HLA-DQB1*0602 multimers was performed as
already described using the Melan-A25-36, Melan-A26-35(A27L), or the HA57-75
peptides (12). Multimer labeling was performed for 1 h at 37jC before
staining with fluorescent monoclonal antibodies (mAb) directed against
surface molecules (20 min at 4jC). FOXP3 labeling was performed ac-
cording to manufacturer’s recommendations. Cells were analyzed by flow
cytometry on a LSR II. For analysis, dead cells were excluded using either
propidium iodide (Sigma-Aldrich) or ethidium monoazide (Molecular
Probes), and all dot plots shown were gated on live CD3+ cells. All mAbs
were purchased from BD Bioscience, with exception for anti-human FOXP3
and anti-human IL-17 mAbs (eBioscience). HLA-A*0201/Melan-A26-35(A27L)
multimers were produced as described (22). Multimer labeling was
performed for 45 min at 4jC.
Intracellular cytokine staining of Melan-A25-36 CD4 T cells. In vitro
peptide stimulations were tested for the presence of cytokine-secreting CD4
T cells. Cells were stimulated for 6 h in the presence or absence of 2 Amol/L
Melan-A25-36, Melan-A26-35(A27L), or irrelevant peptide. Where indicated,
purified anti-DR (L243), anti-DP (B7.21.7), or anti-DQ (SPVL3) were used to
specifically block MHCII recognition (10 Ag/mL). BrefeldinA was added
after the first hour of incubation (10 Ag/mL). After incubation and washing,
cells were stained with anti-CD4 antibody, then fixed and stained intra-
cellularly with anti-IFNg, anti–IL-17 and anti–tumor necrosis factor (TNF)a
or anti–interleukin (IL)-2 antibodies in the presence of Saponin 0.1%.
Samples were analyzed by flow cytometry using an LSRII.
In vitro peptide stimulations with Melan-A25-36 peptide. Total PBMCs
or enriched CD4 T cells in the presence of irradiated CD4 T cells were
stimulated with 2 Amol/L Melan-A25-36 peptide. Two days after addition of
Table 1. Clinical characteristics of melanoma patients
Patient Sex Age* Stage
c
Site of metastasis Treatments Clinical status
b
LAU 50 M 74 IV LNx Surgery, ILP, LUD 01-003k PD
LAU 203 F 62 III LN Surgery, ILP CR
LAU 212 F 71 III LN Surgery, ILP, LUD 96-010{ SD
LAU 270 F 44 IV LN, skin Surgery, ILP, IFNa, LUD 96-010
c
LAU 353 F 49 III LN Surgery, LUD LAU 353
c
LAU 390 F 38 IV LN Surgery, IFNa, chemotherapy, IL-2, LUD 96-010 PD
LAU 470 F 35 III LN, skin Surgery, LUD 96-010
c
LAU 567 F 54 III LN, skin Surgery, LUD 96-010
c
LAU 618 F 73 III LN, skin Surgery, IFNa, ILP, LUD 96-010, LUD 00-018 PD
LAU 706 F 67 III LN, skin Surgery, ILP, p40, LUD 00-018{ PD
LAU 814 M 28 III/IV LN Surgery, LUD 98-009 SD
*Age at diagnosis.
cStage according to the American Joint Committee on Cancer staging system.
bPD, progressive disease; CR, chronic response; SD, stable disease; c, death.
xLN, lymph node; ILP, isolated lymph perfusion.
kImmunotherapy protocols (vaccination with): LUD 01-003 (Melan-A26-35(A27L), NY-ESO-1157-165, Mage-A10254-262, Montanide, s.c.); LUD 96-010
(Melan-A26-35(A27L), Influenza matrix58-66, PBS or AS02B or Montanide); LUD LAU 353 [Melan-A26-35(A27L), Influenza matrix58-66, Montanide, s.c.];
LUD 00-018 [Melan-A26-35(A27L), tyrosinase369-377, CpG 7909, Montanide, s.c.]; p40 [Melan-A26-35(A27L), Klebsiella pneumoniae outer membrane
protein p40, s.c.]; LUD 98-009 [Melan-A26-35(A27L), Mage-A10254-262, Montanide, s.c.].
{Melan-A26-35 instead of Melan-A26-35(A27L).
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peptide, 100 U/mL IL-2 was added to the cultures. After 2 wk, the presence
of specific CD4 T cells was assessed by DQ6/Melan-A25-36 multimers.
cDNA preparation and TCR VB analysis. Five-cell aliquots of multi-
mer+ cells were sorted with a FACS Vantage SE machine directly into wells
of 96-V–bottomed plates. cDNA preparation, cDNA amplification, and PCR
were performed as previously described (23). The quality of each sample
was assessed as described before (24). Aliquots from each sample per
patient and time point were pooled and subjected to individual PCR to
assess the expression of the Vhs as previously published (25). Then, each
five-cell sample was subjected to an individual PCR for each TCR BV chain
positive in the pool.
Statistical analysis. The significance of the results was determined
using Student’s t test. P values of <0.05 were considered significant.
Results are represented graphically as box and whisker diagrams. Bottom
and top of the boxes represent the 25th and 75th percentile, respectively; the
line dividing the boxes indicate the median value, whereas the ends of the
whiskers represent the maximal and minimum values, with exceptions of
outliers that are shown as filled dots.
Results
Characterization of DQ6/Melan-A25-36 CD4 T-cell clones. We
recently identified the Melan-A25-36 peptide as a naturally pro-
cessed epitope presented by the human HLA-DQB1*0602 molecule
(12). We show here that CD4 T-cell clones generated from blood
samples from different metastatic melanoma patients can be con-
sistently labeled with DQ6/Melan-A25-36 multimers (Supplementary
Fig. S1A–C).
As previously reported by us using a single Melan-A25-36–specific
CD4 T-cell clone isolated from a melanoma patient, we further
show here, using multiple independent DQ6/Melan-A25-36 CD4
T-cell clones from additional patients, that they efficiently recog-
nize the dodecapeptide Melan-A25-36, as well as the two amino
acid shorter Melan-A26-35(A27L) analogue decapeptide, as deter-
mined in peptide titration assays (Supplementary Fig. S2A–C).
Because the cytokine responses to DQ6/Melan-A25-36 and A2/
Melan-A26-35(A27L) were comparable in all experiments, we then
assessed whether DQ6/Melan-A25-36 CD4 T-cell clones may also be
labeled using DQ6 multimers loaded with the decapeptide an-
alogue Melan-A26-35(A27L). Interestingly, all the clones tested bound
the DQ6/Melan-A26-35(A27L) multimers, whereas irrelevant clones
did not (Supplementary Fig. S2D).
Naturally acquired Melan-A25-36 CD4 T-cell responses can be
frequently detected in peripheral blood and tumor-infiltrated
lymph nodes from HLA-DQ6 melanoma patients but only
rarely in HDs. To directly monitor HLA-DQ6–restricted CD4 T-cell
Figure 1. Ex vivo detection of Melan-A25-36 CD4 T cells in PBLs and TILNs from healthy donors and melanoma patients, before immunotherapy. A, representative
examples of direct ex vivo labeling of PBLs from HLA-DQ6- (left dot plot ) and HLA-DQ6+ HDs (middle and right dot plots ). B, representative examples of direct
ex vivo labeling of PBLs (top dot plots ) and TILN from HLA-DQ6+ melanoma patients (bottom dot plots ). Percentages in the top right quadrant, frequency of multimer+
within total CD4 T cells. C, graph summarizing ex vivo frequencies of DQ6/Melan-A25-36 multimer+ CD4 T cells in PBLs from HLA-DQ6+ HDs and melanoma
patients, before immunotherapy.
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responses in humans, we first assessed the baseline frequencies of
DQ6/Melan-A25-36 multimer+ CD4 T cells in lymphocytes isolated
from HDs. As expected, no detectable multimer+ CD4 T cells could
be observed in blood samples from 13 HLA-DQB1*0602- donors
(Fig. 1A, left dot plots). In contrast, 3/13 HLA-DQB1*0602+ HDs
showed low but detectable frequencies of DQ6/Melan-A25-36 CD4
T cells. The frequencies of positive cells were 0.01%, 0.01%, and
0.04% for the three donors, respectively (Fig. 1A, middle and right
dot plots). Those cells could be expanded in vitro and secreted Th1
cytokines after stimulation with cognate peptide, suggesting that
they represent circulating Melan-A–specific CD4 T cells in HDs (Sup-
plementary Fig. S3A and B). Remarkably, 10/11 HLA-DQB1*0602+
metastatic melanoma patients presented with variable, but detect-
able frequencies of DQ6/Melan-A25-36 CD4 Tcells in peripheral blood
sampled before any specific immunotherapy (Fig. 1B, top). Overall,
the mean frequency of DQ6/Melan-A25-36 multimer+ CD4 Tcells was
0.005% in DQ6+ HDs and 0.06% (P = 0.03) in melanoma patients
(range, 0–0.29%; Fig. 1C). In addition, we analyzed tumor-infiltrated
lymph nodes (TILN) directly ex vivo from patients LAU 212 and
LAU 50. Thismaterial was surgically removed in both patients before
any immunotherapy. We found an enrichment of multimer+ CD4
T cells compared with autologous peripheral blood lymphocytes
(PBL). Indeed, the frequencies of multimer+ CD4 T cells in these
TILNs were 0.2% and 1.2%, respectively (Fig. 1B, bottom).
Frequencies of DQ6/Melan-A25-36 multimer+ CD4 T cells
ex vivo are not consistently modulated by CD8 T-cell–targeted
immunotherapy. As mentioned above, DQ6/Melan-A25-36 CD4
T cells not only recognize the Melan-A25-36, but also the Melan-
A26-35(A27L) peptide that is recognized by HLA-A2–restricted CD8
T cells. All except one (LAU 203) of the 11 DQ6+ melanoma patients
studied were included in CD8 T-cell–targeted peptide immuno-
therapy trials (Table 1). We therefore determined whether vac-
cination with Melan-A26-35(A27L) had an effect on the frequencies
and/or function of Melan-A–specific CD4 T cells. As exemplified for
two patients in Fig. 2A and summarized for all the patients in
Fig. 2B , higher levels of DQ6/Melan-A25-36 multimer+ CD4 T cells
could be measured during vaccination (range, 0.01–0.66). Moreover,
patient LAU 618 with no detectable multimer+ CD4 T cells in
prevaccine PBMCs had 0.03% and 0.02% of multimer+ CD4 T cells
during immunotherapy. However, no significant overall increase in
Figure 2. Ex vivo longitudinal monitoring
of Melan-A25-36 multimer+ CD4 T cells
in PBLs from melanoma patients
during CTL-based immunotherapy.
A, representative examples of the
longitudinal evolution of ex vivo
Melan-A25-36 CD4 T cells in PBLs from
patients LAU 814 (top ) and LAU 470
(bottom ). Percentages in the top right
quadrant, frequency of multimer+ within
total CD4 T cells. B, graph summarizing
ex vivo frequencies of DQ6/Melan-A25-36
multimer+ CD4 T cells in PBLs from
HLA-DQ6+ melanoma patients,
before and after immunotherapy.
n.s., not significant.
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DQ6/Melan-A25-36 multimer+ CD4 T cells could be detected
(P = 0.78). Furthermore, the frequencies of multimer+ CD4 Tcells did
not correlate to the number of administered vaccines nor to the time
elapsed after initiation of immunotherapy (data not shown).
To confirm that the ex vivo detected DQ6/Melan-A25-36 multimer+
CD4 T cells represent indeed specific cells, these cells were
isolated by flow-cytometry guided sorting and cloned. Indeed,
growing clones were specific for the peptide DQ6/Melan-A25-36 [in
both multimer labeling as well as peptide titration assays (data
not shown)].
Ex vivo FOXP3+ DQ6/Melan-A25-36 multimer+ CD4 T cells are
consistently reduced by CD8 T-cell–targeted immunotherapy.
To assess if phenotype and function of Melan-A25-36 CD4 T cells
might be affected by CD8 T-cell–based vaccination, we combined
ex vivo multimer labeling of CD4 T cells with additional phenotypic
and activation markers. The majority of the Melan-A25-36 CD4
T cells displayed a memory phenotype, already before vaccination,
with different degrees of activation depending on the patients.
We did not observe any significant change in the expression of
differentiation markers (e.g., CCR7 and CD45RA) nor in the
frequency of activated cells (i.e., HLA-DR and CD38) in the post-
vaccination samples (data not shown).
However, remarkably, significant variations were observed in the
frequency of multimer+ CD4 T cells positive for FOXP3, a marker
that identifies regulatory T cells (26, 27), when comparing samples
from a same patient, collected before and after vaccination. Before
vaccination, large proportions (range, 19–74%) of Melan-A25-36 CD4
T cells expressed FOXP3. In contrast, only 1% to 2% of the bulk CD4
T cells were FOXP3+ (Fig. 3A and B). Strikingly, the proportion of
FOXP3+ among multimer+ CD4 T cells dramatically and signifi-
cantly dropped over time during vaccination in all the patients
tested (range, 0–21%; P < 0.001; Fig. 3A and B), whereas the fraction
of positive bulk CD4 T cells remained unchanged. In correlation
with the significant decrease in FOXP3+ Melan-A25-36 CD4 T cells
overtime, we observed, in these same patients, an important ex-
pansion of Melan-A26-35(A27L) CD8 Tcells during vaccination (Fig. 3C).
When assessed in HDs’ samples, FOXP3 expression in ex vivo de-
tected Melan-A25-36 CD4 Tcells was low, being 7%, 4%, and 0% in the
three PBL samples analyzed (Fig. 3A , representative example).
The impaired in vitro proliferative CD4 T-cell response to
Melan-A25-36 is restored during the course of CD8 T-cell–based
immunotherapy and correlates with the drop in FOXP3+
Melan-A25-36 CD4 T cells. In parallel to ex vivo detection of Melan-
A25-36 CD4 T cells, we assessed the functional capacities of these
cells. We performed peptide in vitro stimulations (IVS) using the
Melan-A25-36 peptide of enriched CD4 T cells from prevaccination
and postvaccination PBMC samples. As shown in Fig. 4A , in HDs,
we expanded specific cells only in those samples where ex vivo
detectable Melan-A25-36 CD4 T cells were detected (HD2), whereas
not in those with undetectable frequencies of Melan-A25-36 CD4
T cells (HD1). In melanoma patients, significant expansions were
observed only in the PBMC samples collected after vaccination
(Fig. 4A and B), when the ex vivo frequency of FOXP3+ Melan-A25-36
CD4 T cells was below 10% of multimer+ cells (Fig. 4A and B).
Figure 3. Significant decrease in ex vivo FOXP3+ Melan-A25-36 CD4 T cells in PBLs from melanoma patients during CTL-based immunotherapy. A, representative
example of DQ6/Melan-A25-36 multimer labeling (top ) on PBLs from a HD (left column ) and patient LAU 353, before (middle column ) and after immunotherapy
(right column), combined with FOXP3 analysis in total (middle ) or in Melan-A25-36 CD4 T cells (bottom ). Percentages in the top right quadrants of the dot plots,
frequency of multimer+ cells within total CD4 T cells. B, graph summarizing frequencies of FOXP3+ cells, before and after immunotherapy, in multimer+ or total CD4 T
cells from PBLs from melanoma patients. C, graph summarizing frequencies of A2/Melan-A26-35(A27L) multimer+ CD8 T cells in PBLs from melanoma patients, before
and after immunotherapy.
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Attempts to promote peptide-specific proliferation of Melan-A25-36
CD4 Tcells in prevaccination PBMCs by either depleting CD4+CD25+
T cells or by adding several stimulating or inhibitory molecules in the
culture wells [e.g., CpG-ODNs, CD40L, high doses IL-2, IL-6, IL-15, IL-7,
anti–transforming growth factor (TGF)h, anti–IL-10 receptor] failed
(data not shown).
Finally, the vigorous peptide-specific proliferative response of
Melan-A25-36 CD4 T cells from samples after vaccination was
matched by their ability to secrete Th1 cytokines (e.g., TNF-a),
when incubated with the specific peptide (Fig. 4C). Cytokine
secretion is abolished selectively by anti-DQ antibody but
remained unaffected in the presence of anti-DP and anti-DR
antibodies.
Restriction of TCR VB usage in Melan-A25-36 CD4 T cells
during CD8 T-cell–based immunotherapy. The observation that
the frequencies of FOXP3+ Melan-A25-36 CD4 T cells decreases
during CD8 T-cell–based immunotherapy prompted us to assess
which mechanisms might underlie this phenomenon. To compare
cells from the same antigen specificity at different time points,
we analyzed their TCR Vh usage. We randomly selected three
patients, and isolated multiple five-cell samples of ex vivo DQ6/
Melan-A25-36 multimer+ CD4 T cells by flow cytometry–guided
sorting. Next, we performed PCR for the known different human
TCR Vhs on these samples and compared the results for the same
patient, in samples before and after immunotherapy. As shown in
Fig. 5, a large panel of TCR Vhs is used by Melan-A25-36 CD4
T cells in all the patients, in samples before vaccination (13 by
LAU 50, and 11 by both LAU 814 and LAU 470). In contrast, a
smaller number of Vhs could be amplified in the sorted Melan-
A25-36 CD4 T cells from postvaccination PBMC samples (six for
LAU 814, nine for LAU 50, and two for LAU 470), suggesting a
vaccination-induced restriction of the repertoire. Additional
analysis of the CDR3 sequence of the amplified PCR products
revealed no sequence overlap between cells sharing the same
Vhs, detected before and after vaccination, suggesting a de novo
expansion of specific CD4 T cells with defined Vhs after
immunotherapy (data not shown). Only in the case of patient
LAU 814, the same clonotype (Vh13, CDR3 sequence SPHYNQPQ)
was identified in two independent five-cell samples from PBMCs
collected before vaccination.
Figure 4. In vitro proliferative capacity and functional activity of Melan-A25-36 CD4 T cells from HDs and melanoma patients. A, CD4 T cells from HDs (top ) and
melanoma patients, before and after immunotherapy (bottom ) were stimulated for 14 d in vitro with Melan-A25-36 peptide. Percentages in the top right quadrants,
frequency of multimer+ cells within total CD4 T cells. B, summary of the expansion of Melan-A25-36 CD4 T cells obtained by IVS of PBLs from different melanoma
patients. The fold increase of specific cells has been calculated by dividing % of multimer+ cells after culture by % of multimer+ cells detected ex vivo. Values on the top
of the bars, initial frequencies of ex vivo detected multimer+ CD4 T cells. n.d, not determined. For LAU 50, multiple samples after vaccination have been analyzed.
C, intracellular TNFa labeling on Melan-A25-36 in vitro stimulated CD4 T cells from PBLs from patients LAU 470 (left ) and LAU 814 (right ). Percentages in the
top right quadrants, frequencies of TNFa+ within total CD4 T cells.
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Discussion
The main finding of our work is the direct ex vivo identification,
using pMHCII multimers, of detectable frequencies of circulating
Melan-A25-36–specific CD4 T cells in PBMCs of some DQ6+ HDs
and the majority of DQ6+ metastatic melanoma patients.
Remarkably, vaccination with an exact MHCI-restricted tumor-
associated peptide modulates the phenotype, functionality, and
TCR Vh usage of DQ6-Melan-A multimer+ CD4 T cells. Indeed, we
describe for the first time major reductions in the levels of ex vivo
detected FOXP3+ Melan-A25-36–specific CD4 T cells during the
course of vaccination. The decline in antigen-specific FOXP3+ CD4
T cells is accompanied by a concomitant restoration of their
peptide-specific proliferative potential and cytokine secretion. It is
also associated with a significant restriction of their TCR Vh usage.
Altogether our results suggest a previously unrecognized beneficial
effect of therapeutic vaccination on a tumor antigen–specific CD4
T-cell population.
pMHCII multimers allow direct identification of antigen-specific
CD4 T cells in various clinical situations in humans. However, due
to the low frequencies of circulating antigen-specific CD4 T cells,
this tool has not yet found the same wide usage as pMHCI
multimers. In this regard, reports on the use of pMHCII multimers
in the cancer field are still rare (28–30) and limited to the direct
identification of specific cells after patients’ immunization or after
peptide IVS.
In HDs, both self- and tumor antigen–specific CD4 T cells have
been identified by others. However, in contrast to the findings
reported here, those specific CD4 T cells could not be directly
identified ex vivo but only after multiple rounds of IVS of PBLs
depleted of CD4+CD25+ T cells (31). The Melan-A26-35 that is
embedded in the HLA-DQ6–restricted epitope Melan-A25-36 is
recognized by HLA-A2–restricted CD8 T cells, and high frequencies
of naı¨ve precursors can be identified directly ex vivo with HLA-A2/
Melan-A25-36 multimers in a large proportion of HLA-A2+ HDs (21,
32). Such massive repertoire is generated by a high level of thymic
output and limited turnover in the periphery. Similarly, it can be
speculated that Melan-A25-36 CD4 T cells might be able to escape
thymic-negative selection and accumulate at relative high frequen-
cies in the circulation. In this regard, we failed to ex vivo detect
CD4 T cells specific for other tumor (e.g., NY-ESO-1) or viral (e.g.,
HA) antigens when using pMHCII multimers (data not shown).
The finding that Melan-A25-36 CD4 T cells are present at de-
tectable levels in all but one of the patients’ samples, before
immunotherapy, and at significantly higher frequencies compared
with HDs, argues for a tumor-induced expansion of these cells in
the patients. The cells present a memory phenotype, and more
interestingly, a large proportion expresses the transcription factor
FOXP3. These features suggest that tumor progression selectively
drives the amplification of memory tumor antigen–specific Tregs.
Numerous reports have shown that Tregs are overrepresented in
various cancer types (26, 33–35). Moreover, recent reports docu-
ment on the existence of tumor-antigen specific Treg cells (36–40).
However, no ex vivo data are currently available on the charac-
terization of tumor antigen–specific Treg cells. We provide here
evidence for the presence, in advanced stage melanoma patients, of
relatively high numbers of circulating FOXP3+ Melan-A25-36 CD4
T cells, with low in vitro proliferative potential. These cells may
contribute to the progression of the disease and suppress an
effective antitumor response.
Little is known on the effect of vaccination on antigen-specific
CD4 Tcells in cancer patients. Few clinical trials have been reported
in which melanoma patients were immunized with MHCII- in
conjunction withMHCI peptides. If one trial showed that addition of
MHCII-restricted epitopes to the vaccine formulation did not seem
to improve clinical responses (41), another study reported on Th1/
Th2 responses induced in a small proportion of immunized
patients (29). Furthermore, vaccination using full-length proteins
of defined tumor antigens has resulted in the induction of integ-
rated antibody, Th1, and CD8 T-cell responses (42). In a recent
study on melanoma patients, it was reported that the use of
Salmonella typhimurium engineered to deliver the antigen NY-
ESO-1 elicits CD4 Th1 cells in vitro , which are able to recognize
naturally processed antigen and are resistant to suppression by
Tregs (43). Finally, in a clinical trial in breast cancer patients,
Figure 5. TCR Vh usage by ex vivo detected Melan-A25-36 CD4 T cells in PBLs from melanoma patients, before and after CTL-based immunotherapy. Graphs
indicate TCR Vh usage in ex vivo sorted five-cell samples from PBLs before (top ) and after immunotherapy (bottom ) for patient LAU 814 (A), LAU 50 (B), and LAU 470
(C ). X axis, all the Vh tested; Y axis, CDR3 product length; Z axis, frequencies. Single filled bar, the only TCR clonotype (Vh13, CDR3 sequence SPHYNQPQ)
that was identified twice among the 5-multimer+ cell aliquots in patient LAU 814.
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vaccination with a MHCI-restricted HER2/neu peptide resulted in
a significant decrease in circulating Tregs and TGFh serum levels
in the majority of patients (44). Here, we describe for the first time
the effect of immunization using a MHCI-restricted peptide on
tumor antigen–specific CD4 T cells. We observe that the same
Melan-A26-35(A27L) peptide that induces strong tumor-specific CD8
T-cell responses is able to influence circulating Melan-A25-36 CD4 T
cells in HLA-DQ6+ patients. Indeed, surprisingly, the Melan-A25-36
FOXP3+ and helper CD4 T-cell ratio is reversed during the course
of vaccination. This effect seems to be selective because the levels
of FOXP3+ cells among the multimer- CD4 T cells remained stable
during time. These observations are in contrast with results ob-
tained in mouse tumor models, where immunization of tumor-
bearing animals with tumor antigen recombinant vaccinia virus
resulted in the expansion of tumor-induced Tregs (45, 46). These
discrepancies might be explained by the fact that our vaccination
protocol includes a peptide, Melan-A26-35(A27L), which simulta-
neously targets CD4 and CD8 T cells. In this regard, it has been
reported that immunization of animals bearing methylcholan-
threne-induced sarcomas with the addition of a CTL epitope to the
standard protocol consisting in plasmids encoding self-antigens
resulted in a switch from tumor progression due to expansion of
Tregs to an augmented CTL activity and T-cell help. (47).
In addition to the drop in FOXP3+ Melan-A25-36 CD4 T cells,
immunization also leads to a significant augmentation of the
in vitro proliferative capacity of these cells, as well as to the ability
to secrete Th1 cytokines (e.g., TNFa). As suggested recently (27),
the combined assessment of FOXP3 expression and cytokine
profiles allows to distinguish regulatory from activated
CD4+CD25+ T cells. The molecular and cellular mechanisms
underlying this observation remain poorly understood. One pos-
sibility is that vaccine components, either acting directly on CD4
T cells, or primarily on CD8 T cells and indirectly on CD4 T cells,
promote the generation/expansion of helper Melan-A25-36 CD4
T cells. Thus far, our attempts to reproduce in vitro the ex vivo
observations have failed, probably due to the complexity of the
in vivo situation that cannot be efficiently mimicked in an artificial
in vitro system. To gain further insights into the in vivo mechanism,
we compared the TCR Vh usage of ex vivo detected Melan-A25-36
CD4 T cells, in the same patient, before and after immunotherapy.
The number of TCR Vh segments was significantly reduced in the
specific CD4 T cells from postvaccination samples compared with
the prevaccination baseline values. Thus, it is possible that vac-
cination favored the selective expansion of FOXP3- specific CD4
T cells. Whether the FOXP3+ specific CD4 T cells underwent
apoptosis (48) or simply became undetectable by the spectratyping
technique remains to be addressed. In parallel, we have previously
shown that specific CD8 T-cell responses expanded by vaccination
are characterized by the persistence of only a small number of
highly active and dominant clonotypes (49, 50).8
When feasible, additional ex vivo analyses directly on tumor-
bearing tissues will allow to gain a more detailed picture on the
redistribution of antigen-specific CD4 T cells upon immunization.
Eventually, parameters to correlate immunologic responses with
clinical benefit may be identified.
In conclusion, this study shows for the first time that vaccination
with an exact MHC-I antigenic peptide leads not only to the
efficient induction of MHC-I restricted CD8 T cells but may also
drive the shift from a FOXP3+ MHC II–restricted peptide-specific
CD4 T-cell population to a Th1-like specific response. Because the
same peptide can be recognized by both CD8 and CD4 T cells, it is
tempting to speculate that this class of peptides may be
advantageous for vaccination. This hypothesis needs to be tested
in appropriate animal models, in which the underlying mecha-
nism(s) may be addressed.
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